Ecdysterone Tablet Manufacturing at a Glance
| Parameter | Specification |
|---|---|
| Tablet dosage forms | Uncoated, film-coated |
| Tablet shapes | Round, oval, caplet |
| Beta-Ecdysterone assay | 50%, 60%, 95%, 98%, 99% HPLC |
| Formula options | Single-ingredient, multi-ingredient |
| Tablet weight | Determined by active dose, formula composition, and compression trials |
| Tablet production capacity | 5 million+ tablets/day |
| OEM / ODM / Private Label | Available |
| MOQ | From 5,000 tablets, project-dependent |
| Sample lead time | 10–15 business days after formula confirmation |
| Production lead time | 5–7 weeks after specification and artwork approval |
| Packaging | Bottles, blister packs, and project-specific packaging options |
| Raw material | Beta-Ecdysterone / Ecdysterone extract |
| Formula development | Single-ingredient and custom multi-ingredient formulations |
Common Ecdysterone Tablet Specifications
- Active: Beta-Ecdysterone (20-Hydroxyecdysone)
- Assay grades: 50%, 60%, 95%, 98%, 99% HPLC
- Dosage form: Tablet
- Coating: Uncoated or film-coated
- Capsule alternative: Ecdysterone capsules available for projects requiring a different delivery format
- Formula: Ecdysterone alone or combined with other functional ingredients
- Serving specification: Based on target ecdysterone dose and finished-tablet weight
Project Information Required for Quotation
- Target ecdysterone dose per serving
- Selected ecdysterone assay grade
- Single-ingredient or multi-ingredient formula
- Target tablet weight or serving size
- Tablet shape and coating requirement
- Bottle, blister, or other packaging format
- Target order quantity
- Label and packaging specifications
For raw-material specifications, see the Beta-Ecdysterone Powder Supplier page.
For overall OEM capabilities, see the Ecdysterone Supplement Manufacturer page.
When Tablets Are More Practical for Ecdysterone？
The choice between ecdysterone tablets and capsules depends on active loading, total formula weight, serving size, excipient requirements, coating, and target unit economics.
| Project Requirement | Tablet Suitability | Manufacturing Consideration |
|---|---|---|
| Higher total formula weight per serving | Strong fit | Tablets can accommodate higher total powder loads without relying on larger capsule sizes or multiple capsules per serving |
| High ecdysterone loading | Strong fit | Feasibility depends on assay grade, target active dose, total formula weight, and tablet dimensions |
| High-load co-ingredients | Strong fit | Suitable for formulas containing ingredients such as creatine or other high-inclusion powders when compression characteristics are acceptable |
| Film coating required | Strong fit | Supports taste and odor masking, appearance control, and product differentiation |
| Single-ingredient ecdysterone formula | Strong fit | Simple formulations can be evaluated for direct compression or other suitable tableting approaches |
| Multi-ingredient formula | Strong fit | Formula feasibility depends on powder flow, density, compression behavior, active loading, and target tablet weight |
| Bi-layer or specialized tablet | Project-dependent | Requires formulation and tooling assessment before production |
| Very low total serving weight | Capsule may be preferable | Capsules can be simpler when the formula has a low fill weight and does not require compression or coating |
| Multiple capsules required to reach the target serving | Tablet may be preferable | A larger tablet or multiple-tablet format may provide a more practical serving configuration |
| High-volume, cost-sensitive SKU | Potential advantage | Tablets can offer a competitive unit cost when the formula is suitable for efficient compression and high-volume production |
Tablet vs. Capsule for Ecdysterone
| Consideration | Tablets | Capsules |
| Higher formula weight | Generally more flexible | Limited by capsule size and fill weight |
| High-load formulas | Often suitable | May require larger capsules or multiple capsules |
| Film coating | Available | Not applicable to the capsule shell in the same way |
| Low fill-weight formulas | May be less efficient | Often convenient |
| Consumer preference | Depends on target market | Often preferred for simple powder-based supplements |
| Manufacturing cost | Potentially lower at scale | Can be higher when multiple capsules are required per serving |
| Formula complexity | Suitable for many multi-ingredient formulas | Also suitable, subject to fill-weight and flow constraints |
For projects requiring a lower-fill-weight delivery format, compare the Ecdysterone Capsule Supplement Manufacturer option before finalizing the dosage form.
Key Parameters to Confirm Before Tablet Production
- Target ecdysterone dose per serving
- Ecdysterone assay grade
- Total formula weight per serving
- Number of tablets per serving
- Target tablet weight and dimensions
- Powder flow and bulk density
- Compression characteristics
- Coating requirement
- Co-ingredient loading
- Packaging format
- Target production quantity
Ecdysterone Assay, Raw Material Requirement, and Tablet Weight
Ecdysterone assay directly affects the amount of raw material required to deliver a defined active dose.
For a 500 mg ecdysterone active target, the theoretical raw-material requirement is:
| Ecdysterone Assay | Raw Material Required* | Formulation Impact |
|---|---|---|
| 50% HPLC | 1,000 mg | High active-material loading; larger total tablet weight may be required |
| 60% HPLC | 833 mg | Moderate active-material loading |
| 95% HPLC | 526 mg | Lower raw-material inclusion; more room for excipients or co-ingredients |
| 98% HPLC | 510 mg | Low raw-material inclusion; greater flexibility for tablet-weight control |
| 99% HPLC | 505 mg | Lowest raw-material requirement among the listed grades |
*Theoretical calculation based on assay only: Required raw material = target active dose ÷ assay. Actual formulation requirements may vary according to the material specification and manufacturing process.
For detailed beta-ecdysterone grades, specifications, and bulk ingredient information, see the Beta-Ecdysterone Powder Supplier page.
Why Assay Selection Matters
The assay grade affects more than raw-material quantity. It can influence:
- Total formula weight
- Tablet size and thickness
- Available formulation space
- Co-ingredient loading
- Number of tablets required per serving
- Raw-material cost contribution
- Packaging and shipping considerations
A higher assay is therefore not automatically the better commercial choice. The appropriate grade depends on the target active dose, total formula composition, tablet-size requirements, and target cost.
Final tablet weight is established during formulation development and compression trials after evaluating the complete formula rather than the ecdysterone assay alone.
Tablet Size, Shape, and Fill-Weight Feasibility
Final tablet dimensions depend on total formula weight, bulk density, compression behavior, tablet tooling, and target serving configuration.
| Tablet Format | Typical Application | Key Consideration |
| Round | Single-ingredient and simpler formulas | Suitable for a wide range of standard tablet configurations |
| Oval | Higher-weight formulas | Can provide a more elongated profile for larger tablets |
| Caplet | Higher-weight or multi-ingredient formulas | Common option when tablet length and swallowability need to be considered |
| Scored tablet | Dose-splitting requirements | Requires appropriate formulation, tooling, and tablet-strength assessment |
Parameters Confirmed Before Compression
- Target tablet weight
- Tablet diameter, length, and thickness
- Formula bulk density
- Powder flowability
- Compression behavior
- Tablet hardness
- Friability
- Disintegration requirements
- Coating requirements
- Number of tablets per serving
- Target-market swallowability
A larger total formula weight may require a larger tablet, multiple tablets per serving, or a different dosage-form configuration.
For lower-fill-weight formulas where capsules may offer a more practical format, compare the Ecdysterone Capsule Supplement Manufacturer option.
For higher-serving-weight formulas that may not require compression into a tablet, the Ecdysterone Powder Supplement Manufacturer format can also be considered.
Final tooling and tablet dimensions are confirmed after formulation and compression feasibility testing.
Ecdysterone Tablet Formula Architectures
The following formulas are practical starting points for ecdysterone tablet development. Final ingredient levels, tablet weight, excipient system, and production specifications are confirmed through formulation and compression trials.
Per Serving
- Beta-Ecdysterone — 300 mg
- Creatine Monohydrate — 2,500 mg
- Tablet excipient system — as required
Format: Multi-tablet serving
Best for: Sports-nutrition and performance-focused SKUs.
Manufacturing focus: The 2.8 g active load requires a multi-tablet configuration. Tablet count, total serving weight, and compression feasibility should be confirmed before production.
Per Serving
- Beta-Ecdysterone — 300 mg
- Betaine Anhydrous — 1,000 mg
- L-Citrulline — 1,000 mg
- Tablet excipient system — as required
Format: Multi-tablet serving
Best for: Multi-active sports-nutrition formulations.
Manufacturing focus: The combined active load is approximately 2.3 g per serving. Tablet size, powder flow, and compression behavior determine the final tablet count and weight.
Per Serving
- Beta-Ecdysterone — 300 mg
- HMB — 1,000 mg
- Vitamin D3 — 25 mcg (1,000 IU)
- Tablet excipient system — as required
Format: Tablet
Best for: Sports and active-lifestyle formulations combining a high-load active with a low-dose micronutrient.
Manufacturing focus: HMB determines most of the formula weight, while Vitamin D3 requires controlled low-level dosing and appropriate premix handling.
Per Serving
- Beta-Ecdysterone — 300 mg active
- Zinc — 10–15 mg elemental
- Tablet excipient system — as required
Ecdysterone grade: 95–99% HPLC
Format: Single or multi-tablet serving
Best for: Compact formulas where tablet size and total serving weight are important.
Manufacturing focus: High-assay ecdysterone reduces raw-material inclusion. Zinc source and elemental content should be specified during formulation development.
Tablet compression feasibility is determined by how the complete formula performs during compression, rather than by ecdysterone assay alone.
Powder Flowability
Evaluated for consistent die filling and tablet-weight control, particularly in formulas containing multiple powder ingredients.
Bulk Density
Used to assess whether the target formula weight can fit within the selected tablet dimensions.
Compressibility
Evaluated through pilot compression to determine whether the formula can produce tablets with the required hardness, thickness, and mechanical strength.
Lubrication & Ejection
Lubricant selection and level are optimized to reduce sticking, picking, and ejection problems without unnecessarily affecting tablet performance.
Hardness & Friability
Checked to confirm that tablets can withstand handling, packaging, transport, and normal production conditions.
Disintegration
Evaluated against the finished-product specification after compression and, where applicable, coating.
Film Coating
Assessed for coating compatibility, target weight gain, surface finish, tablet dimensions, and process stability.
Ecdysterone Project Checks
- Selected assay grade
- Target active dose
- Total formula weight
- Co-ingredient loading
- Powder flow
- Compression behavior
- Target tablet specification
- Coating requirements
A formula that meets the target active dose may still require adjustment if it produces excessive weight variation, poor mechanical strength, or an unsuitable tablet profile.
Feasibility testing → Pilot compression → Sample approval → Commercial production
Ecdysterone tablets can be manufactured by direct compression, dry granulation, or wet granulation. The appropriate route is selected according to the physical properties and complexity of the complete formula.
Direct Compression
Used when the powder blend provides suitable flow, uniformity, density, and compression performance without a granulation step.
Key advantage: Fewer processing steps and efficient production when the formula is directly compressible.
Dry Granulation
Considered when the blend requires improved flow or compressibility but moisture exposure should be minimized.
Key advantage: Improves powder handling and compression characteristics without wet processing.
Wet Granulation
Considered when the formulation requires improved particle binding, flow, density, or compression performance through a controlled granulation process.
Key advantage: Provides an additional processing route for formulations that are not suitable for direct compression.
Process Selection
The manufacturing route is determined from:
- Formula composition
- Powder characteristics
- Moisture sensitivity
- Blend uniformity
- Target tablet specification
- Compression performance
- Ingredient compatibility
Lower-assay ecdysterone may increase raw-material inclusion and total powder volume, but assay alone does not determine whether granulation is required.
KS Nutripharma supports direct compression, dry granulation, and wet granulation, allowing the manufacturing route to be selected according to the actual formulation requirements.
Process selection → Pilot production → Sample approval → Commercial scale-up
Coating is selected according to formula characteristics, sensory requirements, tablet specification, packaging, and target cost.
Uncoated Tablet
Best for: Simple formulas and cost-sensitive SKUs.
Consider when: Taste, odor, and appearance do not require additional masking.
Key consideration: Lowest processing complexity and no coating weight gain.
Film-Coated Tablet
Best for: Commercial retail products and formulas where taste, odor, appearance, or swallowing experience requires improvement.
Consider when: The product requires a smoother surface, color differentiation, taste or odor masking, or an additional coating layer.
Key consideration: Coating adds processing steps and finished tablet weight.
Enteric-Coated Tablet
Best for: Specialized formulations with a defined need for delayed release or protection from gastric conditions.
Consider when: The complete formula has a documented delivery requirement that cannot be met by a standard tablet.
Key consideration: Requires additional formulation and coating development and is generally not the default option for single-ingredient ecdysterone tablets.
Coating Selection for Ecdysterone
| Requirement | Suitable Option |
|---|---|
| Lowest processing cost | Uncoated |
| Taste or odor masking | Film-coated |
| Improved tablet appearance | Film-coated |
| Smoother swallowing | Film-coated |
| Specialized delayed-release requirement | Enteric-coated |
Final coating specifications are established according to the formula, target tablet profile, packaging requirements, and finished-product specifications.
Finished-tablet quality is controlled across in-process production, finished-product testing, packaging, and batch documentation. Raw-material identity and incoming-material specifications are covered separately on the Beta-Ecdysterone Powder Supplier page.
In-Process Controls
- Tablet weight and weight variation
- Tablet thickness
- Hardness
- Friability
- Tablet appearance
- Compression consistency
Finished-Product Testing
- Ecdysterone assay
- Disintegration
- Dissolution, where applicable
- Microbiological testing
- Finished-product appearance and specification checks
Packaging Controls
- Tablet count verification
- Container or blister integrity
- Seal integrity
- Desiccant placement, where specified
- Label and batch-information verification
Batch Documentation
- Batch manufacturing records
- Finished-product COA
- Test results against approved specifications
- Stability documentation, where applicable
Finished-product specifications are established according to the approved formula, dosage form, market requirements, and applicable product standards.
Tablet packaging is selected according to tablet count, moisture sensitivity, serving configuration, distribution requirements, and target market.
Bottles
Typical formats: 60-count, 120-count, and 180-count
Materials: HDPE or PET
Suitable for: Retail products and standard daily-use SKUs.
Options: Induction sealing, desiccant, and child-resistant closures where required.
Blister Packs
Typical formats: 10 × 10 or project-specific configurations
Materials: Aluminum-PVC or aluminum-aluminum
Suitable for: Unit-dose presentation, travel formats, and products requiring additional barrier protection.
Foil Sachets
Typical formats: 2-tablet or 4-tablet configurations
Suitable for: Samples, trial programs, and selected unit-dose applications.
Moisture Protection
Desiccant selection and sealing requirements are determined according to the formula, packaging material, and stability requirements. Moisture-sensitive products may require additional barrier protection.
Labeling
Available label formats include pressure-sensitive labels and shrink sleeves, with finished-product labeling prepared according to the approved market and product specifications.
For broader finished-product packaging and OEM options, see the Ecdysterone Supplements Manufacturer page.
| Stage | What Happens | Typical Timing |
|---|---|---|
| 1. Project Brief | Confirm target ecdysterone dose, assay, formula, tablet format, quantity, packaging, and target market. | 1–3 business days |
| 2. Formula & Feasibility Review | Review active loading, tablet weight, ingredient compatibility, compression feasibility, and manufacturing route. | 2–5 business days |
| 3. Sample Development | Finalize formulation, conduct pilot compression, and develop coating where required. | 10–15 business days |
| 4. Sample Approval | Confirm final formula, tablet specifications, packaging, artwork, and production requirements. | Project-dependent |
| 5. Commercial Production | Manufacture the approved formula according to the locked specifications and production plan. | 5–7 weeks |
| 6. QC, Packing & Shipment | Complete finished-product QC, packaging, batch documentation, and shipment preparation. | Included in production schedule |
Typical Lead Time
Sample development: 10–15 business days after formula confirmation.
Commercial production: 5–7 weeks after final formula, specifications, and artwork are approved.
Actual timing may vary according to formula complexity, testing requirements, packaging configuration, order quantity, and material availability.
Information Needed to Start
For an initial feasibility review and quotation, provide:
- Target ecdysterone active dose
- Preferred assay: 50%, 60%, 95%, 98%, or 99% HPLC
- Formula or ingredient list
- Target tablets per serving
- Tablet format and coating preference
- Order quantity
- Packaging requirements
- Target market
Request an Ecdysterone Tablet Manufacturing Quote
Provide the following specifications for a tablet feasibility review and quotation:
- Target ecdysterone active dose: mg per tablet or per serving
- Preferred assay: 50%, 60%, 95%, 98%, or 99% HPLC
- Co-ingredients: ingredient names and target amounts, if applicable
- Tablet format: round, oval, caplet, or other requirement
- Coating: uncoated or film-coated
- Serving configuration: tablets per serving
- Tablet size requirement: target dimensions or maximum acceptable size, if specified
- Packaging: bottle, blister, sachet, or other format
- Target market: country or region
- Estimated order volume: initial and expected production quantity
If the final formula is not yet established, provide the target active dose, key ingredients, preferred tablet format, and estimated quantity. The formulation can then be reviewed for tablet weight, manufacturing feasibility, and production requirements before quotation.
Yes. A project can start with the target ecdysterone dose, assay preference, key co-ingredients, serving configuration, and estimated order volume. The formula can then be reviewed for tablet weight, compression feasibility, and final specifications.
Yes. Customer-supplied formulas can be reviewed against ingredient specifications, tablet dimensions, compression requirements, coating requirements, and production feasibility before commercial manufacturing.
Yes. The same formula can be evaluated as a single-tablet or multi-tablet serving depending on the target active dose, total formula weight, tablet size, and positioning of the finished product.
Potentially, depending on total formula weight, ingredient characteristics, capsule fill capacity, and target serving configuration. For capsule-specific development, see the Ecdysterone Capsule Supplement Manufacturer page.
The most useful starting information is the complete ingredient list with target amounts, ecdysterone assay, target tablet weight or size, serving configuration, coating requirement, and available formula or product specifications.
